Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Fiche publication
Date publication
juillet 2015
Journal
Liver international : official journal of the International Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Sultanik P, Mallet V, Lagaye S, Casrouge A, Dorival C, Barthe Y, Fontaine H, Hézode C, Mottez E, Bronowicki JP, Carrat F, Theodorou I, Abel L, Gayat E, Fontanet A, Pol S, Albert ML,
Lien Pubmed
Résumé
Chronic infection with HCV remains a public health problem with approximately 150 million people infected worldwide. HCV intersects with lipid metabolism for replication and entry; and plasma concentrations of apolipoproteins have been identified as predictors for response to therapy. Herein, we conducted a screen of plasma proteins, including all apolipoproteins, to identify correlates of response to pegylated-interferon/ribavirin (PR) and HCV non-structural protein 3 (NS3) inhibitors (i.e., telaprevir/boceprevir) therapy in treatment-experienced cirrhotic patients from the ANRS CUPIC cohort.
Mots clés
Aged, Antiviral Agents, therapeutic use, Area Under Curve, Biomarkers, blood, Drug Therapy, Combination, Female, France, Hepacivirus, drug effects, Hepatitis C, Chronic, blood, Humans, Interferon-alpha, therapeutic use, Male, Middle Aged, Molecular Targeted Therapy, Oligopeptides, therapeutic use, Polyethylene Glycols, therapeutic use, Predictive Value of Tests, Proline, analogs & derivatives, Prospective Studies, Protease Inhibitors, therapeutic use, RNA, Viral, blood, ROC Curve, Recombinant Proteins, therapeutic use, Ribavirin, therapeutic use, Time Factors, Treatment Outcome, Viral Load, Viral Nonstructural Proteins, antagonists & inhibitors, Virus Replication, drug effects, beta 2-Glycoprotein I, blood
Référence
Liver Int.. 2015 Jul;35(7):1833-44